Purpose

This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices clinical use , including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems into functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be functional biodevices and integrated approaches thoroughly characterized to demonstrate preclinical safety and effective performance in support of specific intended clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

Background

Disease diagnosis relies on a variety of laboratory-based assays including microscopy, tissue and microbial cultures, immunoassays and nucleic-acid amplification. While development of many of these highly-sensitive and robust assays has revolutionized evidence-based diagnostics, in many situations, a continuous, non-invasive real-time assessment would offer additional significant advantages for delivery of evidence-based care.

Advances in biomaterial sciences, biomanufacturing, microfluidics and nanotechnology are leading to development of next generation simple, fast and reliable diagnostic devices, including biosensors, capable of real-time, continuous and noninvasive quantification of biological, chemical, and physical processes for health surveillance and rapid disease detection. Amperometric-, optical-, surface plasmon resonance-, enzymatic-, DNA-, phage-, and bacterial-based biosensors have shown significant promise for detection of a broad spectrum of biological analytes in medical laboratories and food bioanalysis. Such technologies could be utilized in biosensors as well. Additionally, biosensors are increasingly being used to augment therapeutic drug regimens by strengthening patient compliance. As biosensor technologies continue to advance towards smaller more accurate and application-specific integratable, wearable, and embeddable devices, these devices will become important components of medical diagnostics and monitoring that will allow for obtaining clinically-relevant outputs and endpoints indicative of health status, disease progression, and patients compliance with treatment regimens.

Gaps and Opportunities

This FOA seeks to address key technical barriers affecting the safety and overall performance of biodevices specifically designed to function within the oral cavity. While the oral cavity offers unique advantages to access real-time, continuous, noninvasive, physiological measurements, the oral environment presents specific design and performance requirements that need to be addressed according to target clinical applications. Therefore, a systems engineering approach is needed to address major design challenges imposed by the oral environment, including: mastication forces, varying pH levels and temperatures, oral flora, adhesion to wet intraoral tissues, interference with speech, breathing and nutritional intake, material biocompatibility, and prevention of injury to oral tissues.

The oral cavity is an attractive site for developing integrated biosensor-drug delivery-mobile notification devices that would improve treatment of many oral diseases and, in certain cases, would enable systemic delivery of therapeutics in an effective and patient acceptable manner. Such systems would enable precise dosing of medications, enhance medication compliance, and reduce drug-related side effects. Pairing of pharmaceutical products with delivery devices requires close attention to their design, function, and efficacy. An oral biodevice with combined sensing and drug delivery features must consider many different design factors including, drug release profiles, performance requirements dictated by the oral environment and patient acceptance. Design of the release profile for integrated biosensor-drug delivery systems would depend on the condition being treated along with specific parameters of the patient’s metabolism, genetics, epigenetics, diet, and intake of other medications.

Specific Objectives

This FOA seeks to advance meaningful development and substantial optimization of enabling technologies and systems engineering approaches to accelerate innovation and translation of intraoral biosensors and biodevices to clinical practice. Areas of interest include, but are not limited to: Improving the quality of biocompatible materials for optimal device functionality, preventing or minimizing material biofouling and advancing low-power/miniaturized/flexible electronics. In addition, this FOA will support advancing the capabilities of long-term power cells, integrating biosensors with implantable devices and mobile notification systems, securing wireless data transmission and developing technologies that enable reliable adhesion of biosensors and biodevices to wet intraoral tissues.

Examples of research projects may include, but are not limited to the following:

Enabling Technologies

• Development of highly-sensitive and selective biodevices utilizing efficient transducing elements and biosensitive materials to detect small quantities of biomolecules.
• Development of micro/nanoscale biodevices for detection of biomolecules and/or events resulting from enzymatic reactions.
• Development of high fidelity, self-powered, stand-alone, biodevices with secure wireless data transmission to allow adequate quantification and analysis of clinically relevant measures.
• Development of label-free affinity biosensors with demonstrated selectivity, reproducibility and accuracy to chosen analyte(s) tailored to specific applications.
• Optimization of interactions between nanomaterials and biomolecules on the surface of electrodes, and development of biosensor arrays to improve reproducibility and accuracy of molecular detection or simultaneous detection of multiple validated biomarkers.
• Improvement of strategies to ensure materials biocompatibility, device reusability, minimization of device biofouling, enhancement of device shelf-life and improvement of device adhesion to wet intraoral tissues.

Systems Integration and Interoperability

• Development and validation of fully-integrated biosensor-based systems that bring together components of sample preparation and analyte detection with interoperable digital health systems / internet-of-things (IoT) platforms / drug delivery systems / end-user functionality.
• Establishment and validation of biological and engineering solutions for system-level tasks in sensing, interfacing, and designing control processes to improve performance of multi-functional sensors for intraoral applications.
• Development of control systems using dynamically interfaced intraoral biosensors and actuators for flexible, highly-controlled drug release, electrical stimulation and other therapeutic outputs.
• Implementation of smart biodevices that support clinical decision-making for timely assessment and effective treatment of medical conditions.
• Integration and validation of biosensors and processing technologies in embedded, continuous, intraoral diagnostic systems with individualized signal conditioning components for diagnostic and trend-detecting algorithms.
• Miniaturization and integration of biosensor components within an enclosure or a framework adequately designed to conform comfortably to the oral cavity.

Projects that are not responsive to this FOA, and will not be reviewed, include:

• Biomarker discovery.

1. Eligible Applicants

Higher Education Institutions

• Public/State Controlled Institutions of Higher Education
• Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

• Hispanic-serving Institutions
• Historically Black Colleges and Universities (HBCUs)
• Tribally Controlled Colleges and Universities (TCCUs)
• Alaska Native and Native Hawaiian Serving Institutions
• Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

Nonprofits Other Than Institutions of Higher Education

• Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
• Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

• Small Businesses
• For-Profit Organizations (Other than Small Businesses)

Governments

• State Governments
• County Governments
• City or Township Governments
• Special District Governments
• Indian/Native American Tribal Governments (Federally Recognized)
• Indian/Native American Tribal Governments (Other than Federally Recognized)

• U.S. Territory or Possession

• Independent School Districts
• Public Housing Authorities/Indian Housing Authorities
• Native American Tribal Organizations (other than Federally recognized tribal governments)
• Faith-based or Community-based Organizations
• Regional Organizations

Applicant organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

• Dun and Bradstreet Universal Numbering System (DUNS) - All registrations require that applicants be issued a DUNS number. After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application.
• System for Award Management (SAM) (formerly CCR) Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
  • NATO Commercial and Government Entity (NCAGE) Code Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.
• eRA Commons - Applicants must have an active DUNS number and SAM registration in order to complete the eRA Commons registration. Organizations can register with the eRA Commons as they are working through their SAM or Grants.gov registration. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
• Grants.gov Applicants must have an active DUNS number and SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

2. Cost Sharing

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

3. Additional Information on Eligibility

Number of Applications

The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:

• A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
• A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
• An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101)

1. Requesting an Application Package

Buttons to access the online ASSIST system or to download application forms are available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission

For information on Application Submission and Receipt, visit Frequently Asked Questions Application Guide, Electronic Submission of Grant Applications.

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.

By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:

• Descriptive title of proposed activity
• Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
• Names of other key personnel
• Participating institution(s)
• Number and title of this funding opportunity

The letter of intent should be sent to:

Yasaman Shirazi, PhD
Telephone: 301-594-5593
Fax: 301-480-8303
Email: shiraziy@mail.nih.gov

All instructions in the SF424 (R&R) Application Guide must be followed.

Specific Aims: Describe specific aims that will address the FOA's focus to deliver transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization or clinical translation of intraoral biodevices and how the development and integration of such approaches will significantly benefit precision medicine-based detection, diagnosis and treatment of oral and overall health conditions.

This FOA requires the following:

Research plans are to include adequate rationale for design requirements, and design verification/validation activities aimed to establish preclinical safety and effective performance benchmarks of proposed technologies in the context of target clinical applications according to recognized industry standards and FDA regulatory considerations. Product development plans may include preclinical performance testing utilizing benchtop evaluation, animal models and human tissue samples; design validation in actual or simulated use with test subjects, clinicians or end users; and secondary analysis of physiologic data and metadata from existing clinical studies. A systems approach based on technical characteristics and intended clinical use of a proposed biodevice must be applied to product development and performance testing. Performance evaluation should consider testing individual biodevice components and the whole system with respect to biocompatibility, shelf-life stability, mechanical and structural integrity, electromagnetic compatibility, electrical safety, power-cell safety and performance, survivability of the oral environment, cybersecurity, interoperability, usability, biofouling, and any other criteria needed to achieve acceptable performance in the target clinical application.

Adoption of human-factors-engineering and usability-engineering principles need be considered in the development process to ensure that a desired device performance is maximized within the oral environment for the intended use. Implementation of risk assessment and risk management strategies must be considered to reduce design-related problems and potential human safety concerns. A rationale for use must be provided by defining situations in which the proposed intraoral biodevice would provide greater capabilities and quality of care than would be possible with a wearable device outside the oral cavity. Usability criteria such as comfort, discreetness, interference with daily functions of the oral cavity and injury prevention to intraoral tissues must be considered to ensure device safety, and user acceptance and compliance.

For any studies proposing the development of biodevices/biosensors for detecting and monitoring biomarkers, strong evidence demonstrating that all proposed biomarkers have been clinically and functionally validated

The following modifications also apply:

• All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.

If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed.

All instructions in the SF424 (R&R) Application Guide must be followed.

3. Unique Entity Identifier and System for Award Management (SAM)

See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov

4. Submission Dates and Times

Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday , the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

5. Intergovernmental Review (E.O. 12372)

This initiative is not subject to intergovernmental review.

6. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement .

Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

7. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Guidelines for Applicants Experiencing System Issues. For assistance with application submission, contact the Application Submission Contacts in Section VII.

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

1. Criteria

Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.

Significance

Does the project address an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed project rigorous? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Specific to this FOA: Is the novel technology proposed likely to result in new intraoral biodevice technology that can monitor physiological processes in the human body using the oral cavity as the sensing site? How will development and integration of biodevice components significantly benefit biomedical research and/or human health?

Investigator(s)

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

Specific to this FOA: Do the PD(s)/PI(s) and the team possess appropriate interdisciplinary expertise in biology, engineering, medicine/dentistry and other relevant technical areas to handle various aspects of intraoral biodevice development? Is there evidence that the proposed interdisciplinary team can successfully collaborate? Do the PD(s)/PI(s) and the team have a record of previous collaboration?

Innovation

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

Approach

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?

If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified in terms of the scientific goals and research strategy proposed?

Specific to this FOA: Have the investigators presented methods to demonstrate the feasibility of the of biodevice, dedicated biosensors or associated core technologies? Have the investigators identified the benefit of the proposed engineering solution(s) to accelerate the development and translation of intra-oral biodevices to clinical practice? Have the investigators addressed the ability of the biodevice/biosensor to withstand the forces from mastication, enzymes found in the oral cavity, food, changes in temperature, pH, and other unique constituents and conditions of the oral cavity? Have investigators addressed strategies for safe and stable placement of the proposed biodevices in the oral cavity and, in particular, its ability to adhere to tissues in wet environments? Do design verification/validation testing activities seek to benchmark preclinical safety and effectiveness performance of proposed technology according to industry standards (e.g., biocompatibility, shelf-life stability, mechanical and structural integrity, electromagnetic compatibility, electrical safety, usability, interoperability, low-power electronics, long-term power generation capacity, integration with mobile and/or other data capturing devices, software/firmware, power requirements, cybersecurity, biofouling, any other criteria needed to support the targeted clinical application)? Are risk assessment and risk management strategies in place to reduce design-related problems and potential human safety concerns? Was there a strong rationale to support the development of an intraoral biodevice for the target clinical utility in contrast to using a wearable device outside the oral cavity? Are proposed performance testing methods for device safety and effectiveness aligned with recognized industry standards and relevant FDA regulatory considerations? Are project metrics and a timeline clearly articulated and appropriate? For any studies proposing the development of biosensors for detecting and monitoring biomarkers, does the application provide strong evidence demonstrating that all proposed biomarkers have been clinically and functionally validated? Have the investigators adequately described security features that safeguard privacy of data collected on the device and/or transmitted over information technology networks?

Environment

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

Protections for Human Subjects

For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

Inclusion of Women, Minorities, and
Individuals Across the Lifespan

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of individuals of all ages (including children and older adults) to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.

Vertebrate Animals

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.

Biohazards

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

Resubmissions

Not Applicable

Renewals

Not Applicable

Revisions

Applications from Foreign Organizations

Not Applicable .

Select Agent Research

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

Resource Sharing Plans

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) Data Sharing Plan; (2) Sharing Model Organisms; and (3) Genomic Data Sharing Plan (GDS).

Authentication of Key Biological and/or Chemical Resources:

For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.

Budget and Period of Support

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

2. Review and Selection Process

• May undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.

• Will receive a written critique.

• Scientific and technical merit of the proposed project as determined by scientific peer review.
• Availability of funds.
• Relevance of the proposed project to program priorities.

3. Anticipated Announcement and Award Dates

Information regarding the disposition of applications is available in the NIH Grants Policy Statement.

1. Award Notices

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.

Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.

2. Administrative and National Policy Requirements

Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights law. This means that recipients of HHS funds must ensure equal access to their programs without regard to a person’s race, color, national origin, disability, age and, in some circumstances, sex and religion. This includes ensuring your programs are accessible to persons with limited English proficiency. HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.

In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 Federal awarding agency review of risk posed by applicants. This provision will apply to all NIH grants and cooperative agreements except fellowships.

For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA. HHS provides general guidance to recipients of FFA on meeting their legal obligation to take reasonable steps to provide meaningful access to their programs by persons with limited English proficiency. Please see http://www.hhs.gov/ocr/civilrights/resources/laws/revisedlep.html. The HHS Office for Civil Rights also provides guidance on complying with civil rights laws enforced by HHS. Please see http://www.hhs.gov/ocr/civilrights/understanding/section1557/index.html; and http://www.hhs.gov/ocr/civilrights/understanding/index.html. Recipients of FFA also have specific legal obligations for serving qualified individuals with disabilities. Please see http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html. Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at http://www.hhs.gov/ocr/office/about/rgn-hqaddresses.html or call 1-800-368-1019 or TDD 1-800-537-7697. Also note it is an HHS Departmental goal to ensure access to quality, culturally competent care, including long-term services and supports, for vulnerable populations. For further guidance on providing culturally and linguistically appropriate services, recipients should review the National Standards for Culturally and Linguistically Appropriate Services in Health and Health Care at http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53.

3. Reporting

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313). As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 Award Term and Conditions for Recipient Integrity and Performance Matters.

Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

General Grants Information (Questions regarding application processes and NIH grant resources)
Email: GrantsInfo@nih.gov (preferred method of contact)
Telephone: 301-945-7573

Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace)
Contact Center Telephone: 800-518-4726
Email: support@grants.gov